Massachusetts Institute of Technology has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to cyclin-dependent kinase 9 (CDK9)-targeting moiety via linkers acting as CDK9 degradation inducers reported to be useful for the treatment of cancer.
Researchers from Janssen Biotech Inc. and Yuhan Corp. have synthesized EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has discovered proteolysis targeting chimeras (PROTACs) compounds comprising Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety covalently linked to Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
The University of Michigan has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to signal transducer and activator of transcription 3 (STAT3)-targeting moiety via linker acting as STAT3 degradation inducers.
Researchers from The University of Tokyo and affiliated organizations sought to identify molecules within AML cells that suppress NK cell activity, and as such, fully harness the antileukemic functions of NK cells.
Researchers from Sensei Biotherapeutics Inc. presented preclinical data for the novel CD28xVISTA bispecific antibody (BsAb), SNS-201, being developed for the treatment of prostate cancer.
Vironexis Biotherapeutics Inc. came out of stealth mode today, disclosing that it has more than 10 product candidates it’s been developing over the last three years. The therapies are built on the company’s AAV-based platform, Transjoin, which is designed to have patients' livers express bispecific antibodies that bind to both CD3 on T-cells and various targets on tumor cells.
Moderna Inc.’s shares (NASDAQ:MRNA) sank 19% to a $64.11 low in early trading Sept. 12 as investors learned during the annual R&D Day event of a $1.1 billion reduction to R&D and the U.S. FDA’s reluctance to support an accelerated approval filing for its individualized neoantigen therapy for melanoma.
Qure.ai Technologies Private Ltd.’s Qxr artificial intelligence-powered chest X-ray interpretation system identified high-risk pulmonary nodules an average of 32 months before physicians diagnosed lung cancer, a study presented September 8 at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer in San Diego found.
By looking at the electrical activity of tumor cells, rather than the neurons that innervate them, investigators at Baylor College of Medicine have added both basic and translational insights to the emerging field of cancer neuroscience. In their studies, which were published in Cancer Cell on Sept. 5, 2024, the researchers identified the cell of origin for IDH-mutated gliomas.
RSS
